Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001890300 | SCV002155987 | pathogenic | Mucopolysaccharidosis type 6 | 2023-11-20 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 7 of the ARSB gene. While this variant is not anticipated to result in nonsense mediated decay, it likely alters RNA splicing and results in a disrupted protein product. This variant is present in population databases (rs376233975, gnomAD 0.004%). Disruption of this splice site has been observed in individual(s) with mucopolysaccharidosis type VI (PMID: 14974081, 17458871, 24875751). ClinVar contains an entry for this variant (Variation ID: 1382456). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This variant disrupts a region of the ARSB protein in which other variant(s) (p.Asp480Glyfs*3) have been determined to be pathogenic (Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV001890300 | SCV004209136 | likely pathogenic | Mucopolysaccharidosis type 6 | 2023-09-05 | criteria provided, single submitter | clinical testing |